# Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

> **NCT03719898** · PHASE2 · WITHDRAWN · sponsor: **Fox Chase Cancer Center**

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT03719898
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-06
- **Primary completion:** 2020-03-18
- **Final completion:** 2020-06-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719898, "Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03719898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*